Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly (Q26777682)

PubMed

hormonal antineoplastic agent

19 December 2019

1 reference

15 October 2020

1

Annamaria Colao

0 references

Rosario Pivonello

3

Rosario Pivonello

0 references

Leandro Kasuki

4

Leandro Kasuki

0 references

Mônica R Gadelha

5

Mônica R Gadelha

0 references

Renata S Auriemma

2

Creative Commons Attribution 4.0 International

Renata S Auriemma

0 references

language of work or name

English

0 references

publication date

June 2016

0 references

1 June 2016

9 references

24 March 2019

3 April 2019

25 April 2019

13 November 2019

17 November 2019

20 November 2019

27 November 2019

19 December 2019

15 October 2020

10 references

24 March 2019

3 April 2019

25 April 2019

13 November 2019

17 November 2019

20 November 2019

27 November 2019

19 December 2019

15 October 2020

19

0 references

page(s)

235-47

0 references

issue

3

0 references

copyright license

9 references

24 March 2019

3 April 2019

25 April 2019

13 November 2019

17 November 2019

20 November 2019

27 November 2019

19 December 2019

on focus list of Wikimedia project

15 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11102-015-0684-z

0 references

cites work

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Expert consensus document: A consensus on the medical treatment of acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Novel pathway for somatostatin analogs in patients with acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Harmonization of growth hormone measurements with different immunoassays by data adjustment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Resistance to somatostatin analogs in acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Guidelines for acromegaly management: an update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Current concepts in the biochemical assessment of the patient with acromegaly

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Acromegaly: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Use of the oral glucose tolerance test to define remission in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0684-Z

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4858561

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26519143

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26519143

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11102-015-0684-Z

1 reference

Dimensions Publication ID

4250370

1051359339

0 references

Fatcat ID

release_d6mrr7pusfba3gjrc5t2uzhmbe

0 references

4250370

1 reference

1 reference

1 reference